Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 987-993

  Roos, Juliana F ^a   Bulitta, Jurgen ^b   Lipman, Jeffrey ^a   Kirkpatrick, Carl M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

lactams; Critically ill patients; Probability of target attainment

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BIOLOGICAL MODEL; DRUG ADMINISTRATION; DRUG EFFECT; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 34547224444     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl349     Document Type: Article

References (27)

1. Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47: 471-505.
2. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 2005; 55: 601-7.
3. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
4. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7 589-96.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 1-10.
6. Kovarik J, Rozenberg-Arska M, Visser M et al. Pharmacodynamics of cefepime. Scand J Infect Dis Suppl 1990; 74: 270-3.
7. Product Information: Maxipime®, cefepime hydrochloride for injection. (Revised December 2003). Princeton, NJ: Bristol-Myers Squibb Company.
8. Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 2005; 25: 380-4.
9. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-61.
10. Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: The importance of creatinine clearance. Anesth Analg 2003; 97: 1149-54.
11. Steimer JL, Mallet A, Golmard JL et al. Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model. Drug Metab Rev 1984; 15: 265-92.
12. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
13. Beal SL, Sheiner LB. NONMEM User Guides (I-VIII). University of California at San Francisco, San Francisco: University of California NONMEM Project Group, 1998.
14. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
15. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
16. Bulitta J, Holford NH. Assessment of predictive performance of pharmacokinetic models based on plasma and urine data. In: PAGANZ Population Approach Group in Australia & New Zealand 2005; Brisbane, Australia.
17. Oster S, Edelstein H, Cassano K et al. Open trial of cefepime (BMY 28142) for infections in hospitalized patients. Antimicrob Agents Chemother 1990; 34: 954-7.
18. Ismail MM. Disposition kinetics, bioavailability and renal clearance of cefepime in calves. Vet Res Commun 2005; 29: 69-79.
19. Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
20. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003; 22: 982-92.
21. Cherti N, Kinowski JM, Lefrant JY et al. High-performance liquid chromatographic determination of cefepime in human plasma and in urine and dialysis fluid using a column-switching technique. J Chromatogr B Biomed Sci Appl 2001; 754: 377-86.
22. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 2002; 19: 1835-40.
23. Hennig S, Waterhouse TH, Wainwright CE et al. A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis. In: PAGE Population Approach Group in Europe 2006; Belgium.
24. NMusers. Lower Limit of Quantification. http://huxley.phor.com/ nonmem/nm/99jul142005.html, 2005. (July 2006, date last accessed).
25. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983; 11 233-8.
26. Drago L, De Vecchi E, Nicola L et al. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with β-lactams and amikacin. J Antimicrob Chemother 2005; 56: 353-9.
27. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49: 461-3.